Deals this week: Genetic Analysis, Boehringer Ingelheim, Vigene Biosciences

• Boehringer Ingelheim and China South East University Institute of Life Sciences have entered a research agreement to develop new treatments for hearing loss.
• According to the agreement, the two partners will evaluate the key signalling pathways and proteins involved in the regeneration of the inner ear and develop a strategy for drug development.
• The agreement enables the partners to regenerate hair cells from inner ear stem cells.
• Vigene Biosciences has entered a definitive agreement to acquire cGMP manufacturing facility and other assets from Omnia Biologics.
• Shulman, Rogers, Gandal, Prody & Ecker PA is acting as legal advisor for the transaction.
• The transaction will allow Vigene Biosciences to expand its gene and cell therapy product pipeline.
• Laurus Labs Private plans to raise $198m through the initial public offering of its common stock shares.
• Citigroup, Jefferies India Private, Kotak Securities and SBI Capital Markets are acting as lead book runners for the offering.
• The company plans to use the proceeds for repaying its debts and for general corporate purposes.
• Galera Therapeutics has raised $15m in a series B financing round led by Sofinnova Ventures.
• The company plans to use proceeds to advance the phase III trials of GC4419 and also to develop its product pipeline for selective dismutase mimetics.

Deals this week: genetic analysis, boehringer ingelheim, vigene biosciences